Acromegaly is a chronic, slowly developing disease with progressive disfigurement and disability. An early diagnosis is difficult as most signs and symptoms are due to long-standing overproduction of growth hormone &/or insulin-like growth factor (IGF-I) causing metabolic, endocrine and morphological changes.
Surgical intervention is the first-line of treatment for almost all patients with acromegaly unless there are contraindications or the patient refuses to undergo the procedure.

Acromegaly References

  1. Ben-Shlomo A, Melmed S. Acromegaly. Endocrinol Metab Clin North Am. 2008 Mar;37(1):101-122. PMID: 18226732
  2. Bates B. New acromegaly guidelines target premature, mortality, morbidity. Elsevier Global Medical News. 2009 Feb
  3. Keith E. Acromegaly: a new therapy. Cancer Control. 2002 May;9(3):232-235
  4. Katznelson L, Atkinson JL, Cook DM, et al. American Association of Clinical Endocrinologists Medical Guidelines for Clinical Practice for the Diagnosis and Treatment of Acromegaly - 2011 update. Endocr Pract. 2011 Jul;17(4):1-44. PMID: 21846619
  5. Lamberts SW. Acromegaly and its treatment. J Endocrinol. 1997 Oct;155(Suppl 1):S49-S51. PMID: 9389995
  6. Giustina A, Barkan A, Casanueva FF, et al. Criteria for the cure of acromegaly: a consensus statement. J Clin Endocrinol Metab. 2000 Feb;85(2):526-529. PMID: 10690849
  7. Melmed C, Casanueva FF, Cavagnini F, et al; Acromegaly Treatment Consensus Workshop Participants. Consensus: guidelines for acromegaly management. J Clin Endocrinol Metab. 2002 Sep;87(9):4054-4058. PMID: 12213843
  8. Liuzzi A, Oppizzi G. Evidence of ocreotide subcutaneously in the treatment of acromegaly. J Endocrinol. 1997 Oct;155(Suppl Suppl 1):S61-S65. PMID: 9389999
  9. Melmed S, Colao A, Barkan A, et al. Guidelines for acromegaly management: an update. J Clin Endocrinol Metab. 2009 May;94(5):1509-1517. PMID: 19208732
  10. Stewart PM. Current therapy for acromegaly. Trends Endocrinol Metab. 2000 May;11(4):128-132. PMID: 10754533
  11. Patel YC, Ezzat S, Chik CL, et al. Guidelines for the diagnosis and treatment of acromegaly: a Canadian perspective. Clin Invest Med. 2000 Jun;23(3):172-187. PMID: 10911548
  12. Trainer PJ, Drake WM, Katznelson L, et al. Treatment of acromegaly with the growth hormone-receptor antagonist pegvisomant. N Engl J Med. 2000 Apr;342(16):1171-1177. PMID: 10770982
  13. Zaloga GP, Marik P. AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract. 2004 May;10(3):213-225. PMID: 15382339
  14. MedWorm
  15. Khabdwala HM. Acromegaly. eMedicine. May 2005
  16. Melmed S. Treatment of acromegaly. UpToDate. 2001
  17. Shim M. Gigantism and acromegaly. eMedicine. Mar 2002
  18. The Endocrine Society. Clinical control, anti-tumor and anti-proliferative effects with somatostatin analogues. Medscape. 2002
  19. MedWorm
  20. MedWorm - Acromegaly
  21. AACE Acromegaly Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the diagnosis and treatment of acromegaly. Endocrine Pract. 2004 May;10(3):213-225.
  22. Melmed S, Jameson JL. Disorders of the anterior pituitary and hypothalamus. In: Jameson JL. Harrison’s Endocrinology. 2nd ed. New York: McGraw-Hill; 2010:16-49.
  23. Katznelson L, Laws ER Jr, Melmed S, et al. Acromegaly: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014 Nov;99(11):3933-3951. doi: 10.1210/jc.2014-2700. PMID: 25356808
  24. Chanson P, Salenave S, Kamenicky P, et al. Pituitary tumors: acromegaly. Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):555-574. doi: 10.1016/j.beem.2009.05.010. Accessed 27 Jul 2017. PMID: 19945023
  25. Melmed S. Causes and clinical manifestations of acromegaly. UpToDate. Oct 2015.
  26. Melmed S. Diagnosis of acromegaly. UpToDate. Aug 2015.
  27. Melmed S, Bronstein MD, Chanson P, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018 Sep;14(9):552-561. doi: 1038/s41574-018-0058-5. PMID: 30050156
  28. Zahr R, Fleseriu M. Updates in diagnosis and treatment of acromegaly. Eur Endocrinol. 2018 Sep;14(2):57-61. doi: 10.17925/EE.2018.14.2.57. PMID: 30349595
  29. Lugo G, Pena L, Cordido F. Clinical manifestations and diagnosis of acromegaly. Int J Endocrinol. 2012;2012:540398. doi: 10.1155/2012/540398. PMID: 22518126
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Endocrinology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
Regular practice of yoga postures confers benefits for glucose control, oxidative stress, inflammatory response, and sleep quality in patients with type 2 diabetes, a study has found.
01 Dec 2020
Tetanus toxoid 5 Lf, diphtheria toxoid 2 Lf, pertussis toxoid 2.5 mcg, filamentous haemagglutinin 5 mcg, fimbriae types 2 and 3 5 mcg, pertactin 3 mcg
Dr. Hsu Li Yang, Dr. Tan Thuan Tong, Dr. Andrea Kwa, 08 Jan 2021
Antimicrobial resistance has become increasingly dire as the rapid emergence of drug resistance, especially gram-negative pathogens, has outpaced the development of new antibiotics. At a recent virtual symposium, Dr Hsu Li Yang, Vice Dean (Global Health) and Programme Leader (Infectious Diseases), NUS Saw Swee Hock School of Public Health, presented epidemiological data on multidrug-resistant (MDR) gram-negative bacteria (GNB) in Asia, while Dr Tan Thuan Tong, Head and Senior Consultant, Department of Infectious Diseases, Singapore General Hospital (SGH), focused on the role of ceftazidime-avibactam in MDR GNB infections. Dr Andrea Kwa, Assistant Director of Research, Department of Pharmacy, SGH, joined the panel in an interactive fireside chat, to discuss challenges, practical considerations, and solutions in MDR gram-negative infections. This Pfizer-sponsored symposium was chaired by Dr Ng Shin Yi, Head and Senior Consultant of Surgical Intensive Care, SGH.
6 days ago
Women with central adiposity, regardless of menopausal status, are at risk of developing breast cancer, according to a study.